You are on page 1of 43

Board of Directors Shri K Raghavendra Rao, Chairman & Managing Director Shri K Raghavendra Rao has a Bachelors Degree

in Commerce from Andhra University and a PostGraduate Diploma in Management from IIM-Ahmedabad. He is also a member of The Institute of Cost & Works Accountants of India and The Institute of Company Secretaries of India. He is the Founder and Chairman and Managing Director of Orchid. Prior to establishing Orchid, he was associated with leading organisations in India in various capacities. He was singularly responsible for developing a multi-business conglomerate in the Gulf, which included the regions first ever bulk drugs plant. Shri S Krishnan, Executive Director - Finance Shri S Krishnan has been associated with Orchid for around a decade and has been heading the finance function in the last few years. He has a rich and diversified experience of over 24 years in the field of finance and Accounts. He possesses a degree in Bachelor of Science from the University of Madras and is also a member of the Institute of Chartered Accountants of India and the Institute of Company secretaries of India. Shri S Krishnan in addition to his executive responsibilities as a Board member also holds the current role of Chief Financial Officer of the company. Shri K Biju George, Nominee Director - IDBI Shri K Biju George has 22 years of vast experience in Project Management and Project Finance. He has a decade long association with premier Financial Institution / Commercial Bank in India; where since last three years, he is in charge of Infrastructure Corporate Group, handling accounts of Kerala & Tamil Nadu. Shri K Biju George also has a vast industrial experience in the field of Projects, Planning & Maintenance in Chemical, Petrochemical & Manufacturing sectors. Shri Deepak Vaidya Shri Deepak Vaidya holds a commerce degree from the University of Mumbai and is a fellow member of the Institute of Chartered Accountants, England and Wales. He has been on the Board of Orchid since 1999 and is also a member of the Audit Committee and Remuneration Committee. Shri Bharat D. Shah Shri Bharat D. Shah is one of the founder members of HDFC Bank. He has served in various organisations such as Pyrene Company Limited, Bradma India Limited, Technova, Thomas Cook, Citibank and had been an Investment Advisor for Union Bank of Switzerland, Singapore. He is presently the Chairman of HDFC Securities Limited. Shri Bharat Shah is a B.Sc graduate from the Bombay University and holds a Higher National Diploma in Applied Chemistry from London University. Prof. Bala V. Balachandran Prof. Bala V. Balachandran is a PhD in Industrial Administration and an MBA from Carnegie Mellon University. He is also a Certified Public Accountant, Certified Management Accountant and Certified Internal Auditor. Currently, he is involved with the Ministry of Corporate Affairs in setting up of the Indian Institute of Corporate Affairs. He is the Founder & Dean of Great Lakes Institute of Management and also the Founder & President of Mumbai Business School in India. Additionally, he is Executive

Professor & Strategy Advisor to the Dean, Bauer College, University of Houston and J. L. Kellogg's Distinguished Professor (Emeritus in service) of Accounting and Information Management, Northwestern University in USA. He was awarded the Padma Shri in 2001.

Management Team
Dr. B Gopalan CSO Ms. Edna Braganza Chief Operating Officer API Mr. M S Rangesh Chief Human Resource Officer Mr. V Vijayendran Chief Executive Domestic Formulations Mr. S Mani - President Process Research, SH&E and CSR Dr. R Buchi Reddy Executive Vice President Process Research Mr. P N Deshpande Executive Vice President Manufacturing Dr. Shridhar Narayanan Executive Vice President Biology Mr. S Sridharan Executive Vice President IT & IE Mr. V S Padalkar Senior Vice President Engineering & Production Mr. K V V Raju Senior Vice President Technical Operations Dr. U P Senthil Kumar Senior Vice President Process Research Dr. Shashank Narayanrao Lulay Senior Vice President QA Dr. C V Srinivasan Senior Vice President Medicinal Chemistry Dr. J Surya Kumar Senior Vice President Formulation Development Mr. Deepak M B Nayyar Vice President Domestic Formulations Mr. Gurmeet Singh Vice President Commercial Mr. V C Nagaraj Vice President Human Resources Mr. Sampath Parthasarthy Vice President Domestic Formulations

Mr. P Sreenivasa Rao - Vice President QA & RA Mr. A Suresh Babu Vice President Corporate Affairs

Innovation drives growth. Sensitive to market needs and committed to innovation, here at Orchid we focus on niche product manufacturing platforms, combining cutting-edge technology and the best minds in the business. Valuing People We value individuality and creativity. Our unique People and Process Paradigm helps achieve the twin objective emphasis on regulatory and compliance on one hand, while fostering innovation and creativity on the other. Peak Performance We seek to build a sustainable organisational eco-system where one is constantly motivated to attain new heights and empowered to discover new avenues for growth. Quality Quality has always been a strong part of Orchids proposition. Our quality initiative covers all aspects including product quality, operational quality, environmental quality and finally a good quality of life for our people. Harmony with Society We seek to balance environmental impact and economic interest in all our business activities. Committed to the development of the society, culture and economy, we dutifully observe laws; demonstrate high ethical standards and endeavour to preserve the environment.

Vision & Mission Vision

Enriching Lives through Innovation in Healthcare


"Discovery to Delivery" Orchid is a vertically integrated pharmaceutical company with established research, manufacturing and marketing capabilities across multi-therapeutic domains. We successfully leverage our penchant for science and technology to create niche products and manufacturing platforms leading to attractive growth.

Most organisations are mostly driven by strategies. We are also driven by values.

Corporate Social Responsibility Respect for the Individual Excellence Innovation Value for Stakeholders

History & Milestones 1992

Orchid Chemicals & Pharmaceuticals Ltd. is established on 1st July and obtains the Certificate for Commencement of Business. The company undertakes to set up a 100% EOU (export oriented unit) for manufacture of 90 TPA of cephalosporin antibiotics.


Goes public and issues shares, subscribed & paid-up.


Starts commercial production. Receives Good Manufacturing Practice (GMP) Certification.


Sets up a state-of-the-art formulation facility exclusively for manufacture of sterile cephalosporin formulations. Receives ISO Certification for Quality Systems. Commissions sterile lyophilisation plant.


Becomes the youngest Indian pharmaceutical company to receive the ISO 9002 Certification. Commissions the R&D Centre. Launches a range of new products in the sterile category. Becomes country's largest producer of oral and sterile cephalosporin. Is ranked among the top five producers of cephalosporin APIs.


Orchid Healthcare, the formulations division becomes operational.


Receives ISO Certification for Environment Management Systems.


Acquires a manufacturing plant at Aurangabad. Commissions plant for manufacturing nutraceutials.


Receives the ISO 9001:2000 Certification. Sets up a joint venture alliance with a US-based drug discovery research firm Bexel Biotechnology Inc, USA (Bexel). Sets up an office in USA. Enters into a joint venture with NCPC to set up a manufacturing joint venture in China.


Acquires domestic formulations company, Mano Pharmaceuticals and enters the chronic therapy segment. Sets up an office in Russia.

Inaugurates new Corporate Office. Commissions state-of-the-art Good Laboratory Practices (GLP) compliant pre-clinical facility to support drug discovery. Signs an exclusive pact with Apotex to market select sterile antibiotic dosage forms in USA. Formulation facilities receive the Therapeutic Goods Administration (TGA) approval. Enables marketing range of cephalosporin bulk drugs (sterile & non-sterile) and noncephalosporin formulations in Australia and New Zealand. European Directorate for the Quality of Medicines (EDQM) & United Kingdom Medicines and Healthcare Regulatory Agency (UK MHRA) successfully inspects API facilities. Joint venture with Bexel moves its novel anti-diabetic molecule (BLX-1002) into human clinicals. Aurangabad API facility is awarded ISO 14001 and OHSAS 18001 Certification.


Joint venture with Bexel successfully completes Phase 1 (a) clinical trials on its lead antidiabetic molecule (BLX-1002). Joint venture with Bexel successfully completes Phase 1(b) clinical trials on its lead antidiabetic molecule (BLX-1002). Signs an agreement with Par Pharmaceuticals to market oral cephalosporin formulations in US market. Enters into an agreement with Apotex Inc. for an exclusive marketing pact in the Canadian market. Joint venture with Bexel successfully completes Phase 2(a) trials on its lead anti-diabetic molecule (BLX-1002). Molecule receives patent clearance from US patent office. Enters into a marketing agreement with Par Pharma for non-penicillin and noncephalosporin (NPNC) products. Enters into an agreement with Phoenix for key veterinary injectable product.


Inks pact with Alpharma to market NPNC dosage forms in US & European markets. Enters into a marketing agreement with STADA Pharmaceuticals (USA) for NPNC products. Receives GLP Certification. Becomes fifth company in India to be certified for its R&D expertise. His Excellency, the then Hon'ble President of India Dr. A.P.J. Abdul Kalam visits Orchid's state-of-the-art formulations manufacturing complex located in the SIPCOT Industrial Estate, Irungattukottai, near Sriperumbudur. Medicinal chemistry labs are commissioned in the New Drug Discovery center. Enters into an agreement with Mayne Pharma (now Hospira) for marketing injectable antibiotic formulations in selected regulated markets (US, Europe and ANZ).

Enters into a long-term Master Agreement with Pfizer for certain custom research and manufacturing services (CRAMS).


Undertakes structural consolidation of global discovery research. Acquires 100% of US discovery entity, Bexel Pharmaceuticals. Cephalosporin API and FDF facilities receives UK MHRA approval. Signs deal with Biovitrum in drug discovery field.


UK MHRA approves betalactam API facility located in Aurangabad, near Mumbai. Enters into a licensing and distribution alliance with Actavis to market cephalosporin formulations in Europe. Forays into the Canadian generic formulations market. Receives Canadian Therapeutic Product Directorate (TPD) approval for two generic formulations. Enters into a marketing arrangement with a leading distribution house for oral cephalosporin and non-cephalosporin products. Completes the sterile carbapenem API facility in Aurangabad.


Formulation facilities that manufacture a range of cephalosporin and penicillin injections approved by the Medicines Control Council (MCC), South Africa. Completes the sterile carbapenem dosage form facility at Irungattukottai, Chennai. Receives the Piperacillin-Tazobactum dossier and ANDS approvals for Australian and Canadian markets. Sets up a wholly owned subsidiary in Japan called Orchid Pharma Japan K K (Orchid Japan) to capitalise on the growing Japanese market. Undertakes the development of a Novel Anti-coagulant Drug Candidate from Merck and invests in Diakron Pharmaceuticals Inc. (Diakron), a US-based drug discovery and development company, which has an exclusive license agreement with Merck for the compound. Enters into a research collaboration and license agreement with Merck to discover, develop and commercialise molecules essential for the treatment of bacterial and fungal infections.


US FDA approves ANDA for Piperacillin and Tazobactum injection with 6 months exclusivity.

Orchid inks business transaction agreement with Hospira to transfer the generic injectables formulations dosage form pharmaceutical business for USD 400 million.


Completes business transfer transaction for sale and transfer of its generic injectable finished dosage forms pharmaceuticals business to Hospira. Collaborates with Alvogen to license and market its eight oral non-antibiotic generic formulations. Acquires US-based marketing company Karalex Pharma, to strengthen its presence in the front-end US market and to reach its generic products to the US customers directly. Orchid redeems FCCBs aggregating to USD 25.69 million.


Cephalosporin API manufacturing facility at Alathur was successfully re-inspected by USFDA. Orchid received milestone payment from Merck on advancement of their research initiative to discover, develop and commercialize molecules essential for the treatment of bacterial and fungal infections. Orchid's API Manufacturing facility at Alathur was awarded with OHSAS 18000 : 2007 (Occupational Health and Safety Management System) certification. Orchid's API Manufacturing facility at Alathur was re-assessed and was certified with ISO 9001 : 2008 (Quality Management System) and ISO 14001 : 2004 (Environmental Management System).


Orchid Pharma successfully completed in Europe a Phase I trial of its orally administered PDE4 (phosphodiesterase 4 inhibitor) molecule OCID 2987 positioned for the treatment of inflammatory disorders including COPD (Chronic Obstructive Pulmonary Disease). Orchid successfully redeemed the outstanding FCCBs, including yield-to-maturity, aggregating to USD 167.64 million. Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira.

Corporate Governance Our Approach

Ever since our inception, we committed ourselves to the highest standards of corporate governance. We believe that a robust corporate governance policy drives healthy business growth and reinforces vibrant markets, besides serving an important instrument of investor protection. Governance also provides an appropriate framework for the Board and the Management to set corporate objectives to enhance shareholder value.

Core Values
Our corporate governance is defined by clear, established values, standards of business conduct and code of ethics.

Business Ethics
Our business code reaffirms our adherence to core values and serves as a practical guide to everyday work life. Constantly accommodating new legal and regulatory developments, this code is a valuable resource in assisting employees with decision making to ensure that business is conducted with integrity. This business code also helps in preventing, detecting, reporting and addressing any allegation of misconduct and violations of law.

Adhering to the principle of fair disclosure, we regularly provide information on the companys position and significant changes in business activities to all our stakeholders.

Safety Excellence Safety First

At Orchid, safety is a part of the corporate culture. This includes infrastructural, employee, environmental and community safety. Starting with the employee induction programme, training programmes on various aspects of operational safety are periodically conducted. In association with a global expert on safety procedures, a number of initiatives have been designed to ensure that all manufacturing processes and systems are executed in the safest manner. These include:

Use of high-end technologies to recycle discharge and make it toxic free through a series of processes thereby leading to zero discharge manufacturing Three-tier safety committees to monitor safety initiatives, standard operating procedures (SOPs), process and working standards for R&D and manufacturing units Round-the-clock medical care and safety training for all employees Use of sophisticated equipment in mobile vans to monitor air quality inside and outside plants

Safety vision
To become a world-class, safety-driven pharmaceutical organisation by conducting our business processes and operations with commitment to the highest standards of safety, health and environment.

Safety goal
Our safety vision is inspired by a succinctly stated goal 'Zero Incident'. We believe the goal of a zero incident workplace is achievable by developing and maintaining management systems that allow us to control risk by ensuring engineering controls and administrative controls. Our ultimate goal is to have zero accidents, zero injuries and zero fatalities leading to zero incidents.

Our Safety Principles

The company formulated seven safety principles:

Safety is a core organisational value. Management is responsible for preventing injuries. All injuries can be prevented and occupational exposures minimised. All incidents must be reported and acted upon. Working safely is a condition of employment and contract. Training employees in safety is essential. Safety makes good business.

Tara Our face of safety

At Orchid, safety is a culture and has always been kept at the forefront. We treasure our employees and value our infrastructure thereby inculcating the highest levels of safety standards. Tara represents our movement for a safer world. Tara was born as the outcome of our desire to have a symbol that reinforces our concern for

safe practices for a safer world. Tara, a young girl child reminds someone is waiting back home an emotional imperative to consciously adhere to safe practices. She communicates a simple reality that safety is important not just for us today, but for our future generations as well.

We accord the highest emphasis to quality and it is given as much attention as innovation and value creation. A fully computerised quality control system monitors operations round-the-clock thereby ensuring highest standards of quality.

At Orchid, maintaining highest levels of quality helps us deliver excellence in everything we do reflecting not only in robust growth but also in personal development and enhanced management abilities.

Our manufacturing facilities deploy state-of-the-art technologies and automated facilities that ensure the highest levels of process integrity and product quality. Our facilities have fully selfreliant Quality Control departments with sophisticated equipment such as HPLCs, GCs, titrators, FTIRs and UV spectrometers to ensure conformance to stringent quality standards. Our sterile plants (for both crystallisation and lyophillisation) have been built with European equipment, fabrication and support systems. Our facilities have successfully gone through several inspections by the US FDA and UK MHRA among others, enabling a steady flow of product approvals. We have also established an end-to-end connected infrastructure for drug discovery and development in Chennai (India) to meet world-class standards with associated facilities for process research, pharma research and biotechnology.

Our world-class quality products and facilities, regulatory and compliance systems conform to international standards. In fact, we have been the youngest pharmaceutical company in India to receive the coveted ISO Certification.

Environment Sustainability

Sustainability is one of our core values, and integral to our overall vision in shaping a dream. As a responsible member of the society, we realise that we cannot alienate ourselves from the ecosystem and we have to give back to the world what we take. We know we operate in a sector that can have a significant impact on the environment, which means we have an even greater responsibility to make sure we use resources wisely, and manage our waste and emissions effectively. We have been awarded the coveted ISO 14001-Quality Certification for our Quality Environment Management Systems. Our facilities are the first and among the few 'zero discharge' pharmaceutical facilities in India. We also have sophisticated technologies for vent gas condensation, solvent re-circulation and reverse osmosis. Significant resources have also been invested in putting up world-class effluent treatment infrastructure regarded as a showcase in the Indian pharmaceutical industry. In addition, we also have a mobile vehicle equipped with state-of-the-art monitoring equipments to constantly measure the quality of ambient air in and around our manufacturing facilities. Our green policies have earned us the reputation of being a pioneer in Environmental Management Systems and have won appreciation from various delegates including the Confederation of Indian Industry (CII). The Government of India and various industry apex associations have also awarded us the Gold standard in Environmental Safety and Protection.

Awards & Accolades

Awards and accolades have been an important part of the Orchid success story. Over the years, Orchid has received many awards and accolades in recognition of its pioneering achievements.

General Awards Orchid Research Laboratories Limited (ORLL), the wholly-owned drug discovery subsidiary was conferred the Frost & Sullivan Award for Partner of Choice in Contract Research Collaborative Drug Discovery in 2007.

Orchid was awarded the Employer-Employee Relation Award in the Large Scale Industry category by the Rotary Club of Madras South West in 2006.

Orchid was awarded the prestigious Partner of Choice for Competitive Excellence Award by Frost & Sullivan in 2005.

In 2002 Orchid was awarded the MMA Award for Managerial Excellence in the Manufacturing sector by the then Governor of Tamil Nadu, Honble Shri. PS Ramamohan Rao. Performance / Quality Awards Orchid was conferred with the Export Excellence Award 2010-11 by MEPZ Special Economic Zone, Government of India.

Orchid received EXIM Achievement Award 2011 for its meritorious export performance under the category Air Exports by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred the Gold Patent Award for the year 2010-11 in recognition of its commendable contribution to R&D in Drug Discovery Sector by the Pharmaceutical Export Promotion Council. The award was presented by Shri. N. Kiran Kumar Reddy, Honble Chief Minister of Andhra Pradesh.

Orchids manufacturing facility located in Aurangabad (Maharashtra) was honoured with the Facility of the Year Award 2009 (Regional Excellence Category) by ISPE, Interphex and the Pharmaceutical Processing magazine.

Orchid was awarded the EXIM Achievement Award 2007-08 for its meritorious export performance by the Tamil Chamber of Commerce, Chennai.

In 2003, Orchid was awarded the Gold Award for Excellence and Business Prestige at the Quality Summit 2003, New York.

Orchid was awarded the trophy for Excellent Performance in Exports for 1998-99 from the then Prime Minister of India, Hon'ble Atal Behari Vajpayee held at Vigyan Bhavan, New Delhi.

Orchid received the Industrial Economists Business Excellence Award 1996-97 for meritorious performance.

Orchid has been consecutively awarded the CEU Export Award for its commendable export performance in 1994-95, 1995-96 and 1996-97.

Orchid was awarded the Trophy for meritorious performance in exports for the year 1995-96, by the Ministry of Commerce, Government of India and the award was given by the then President of India, Shri. Shankar Dayal Sharma.

Orchid was selected by The All India Manufacturers Organisation (Tamil Nadu State Board) for the Visvesvaraya Industrial Award for its performance during 1995-96. CSR Awards Orchids social responsibility initiatives were honoured by the Tamil Nadu Government with the Award for Corporate Social Responsibility for the year 2008-09.

Orchid was awarded the Environment & Community Service Award 2003-04 by the Rotary Club of Madras.

Orchid was adjudged as the Best Corporate Citizen for the year 2000 and was awarded the prestigious, "Mother Teresa Award", by the Loyola Institute of Business Administration in 2001. Environment Awards Orchid was awarded IGCW 2011 Green Innovation Award for the outstanding research in the field of Green Chemistry & Engineering in 2011.

Orchid was conferred the Shrishti Good Green Governance (G3) Award in 2011. The award was presented by Mr. Salman Khurshid, Minister of Water Resources & Minority Affairs, Government of India.

In 2010, for "Outstanding Achievement in Environment Management in the Chemical sector", Orchid was conferred with the Silver Award by Greentech Foundation.

Orchid was awarded the "Siemens Ecovatives-IBN Live Award 2010" in recognition of our outstanding initiatives in Energy Management (Low Energy and Natural Resource Conservation).

In 2010, Orchids Alathur API facility received the Bureau of Energy Efficiency (BEE) Certificate of Merit on Energy Efficiency by the Ministry of Power, Government of India.

Orchids endeavour in the area of energy conservation was recognised with the Excellent Energy Efficient Unit in the 9th Energy Efficiency Summit 2010 organised by the CII (Confederation of Indian Industries). This award was recently presented by Mr.Ajay Mathur, Director General of Bureau of Energy Efficiency, Ministry of Power, and Government of India.

Orchids Aurangabad facility received the Dr.R J Rathi Award for Environment Pollution & Control in industries in Maharashtra for the year 2010 (constituted by Maharashtra Chamber of Commerce Industries & Agriculture, Pune).

Orchids endeavor in the area of Environmental Excellence was recognised with the TERI Corporate Award for Environmental Excellence 2009. The award was presented by the Honble President of India, Smt. Pratibha Devisingh Patil.

In 2008, Orchids Alathur Unit was conferred with the National Energy Conservation Award 2008 (Drugs & Pharmaceuticals sector) by the Ministry of Power, Government of India.

Orchid was awarded the Good Green Governance Award 2007 in the Manufacturing (nonmetallurgical) category by the Srishti Group of Publications.

Orchids world-class Environment Management Systems were conferred with yet another accolade in 2003, i.e., MS Swaminathan Award for Environment Management.

In 2003, Orchids remarkable achievements in the area of environment protection were recognized with the 'Golden Peacock Award'.

Orchids Alathur facility was awarded the prestigious Excellent Energy Efficient Unit award, a National Award for Excellence in Energy Management by the CII in 2002 as well as in 2001.

Orchid was nominated among Indias Greenest Companies listing by the Business Today magazine in 2001. Safety Awards In 2011, Orchid received the "Green Tech Gold Safety Award" by Greentech Foundation. The award was presented by Dr RK Srivastav, Director General of Health Services, Ministry of Health & Family Welfare, Gov of India and Mr Kamaleshwar Sharan, President, Greentech Foundation.

Orchids Alathur facility received the Greentech Safety Award 2010 (Silver award) in pharmaceutical sector for outstanding achievement in Safety Management given by Greentech Foundation.

Orchid was awarded the "Certificate of Merit Award" for 2010 by the CII for Excellence in Environment, Health and Safety.

Orchid was awarded the Certificate of Merit for Excellence in Management of Safety, Health & Environment (SHE) for the year 2008 by the Indian Chemical Council (ICC).

Orchid has been awarded the Leadership & Excellence Award in Safety, Health, and Environment & Manufacturing by the CII in 2002.

Orchid Trust Placing community before commerce

As a global pharmaceutical corporation, our desire to cure extends beyond health care, spilling over to ills in the social and economic arenas. This sensitivity to the community related issues has spurred us into creating a development trust, which has embarked on a variety of projects, aimed at the socially and economically deprived sections.

Our Mission
To accelerate sustainable development of rural areas by empowering socially and economically deprived sections.

Orchid's Tripartite Approach

Our community development agenda is derived from the belief that community benefits grow when industry, government and institutions work collaboratively. Government: It has the mechanics to receive and document the needs of society. It also has the legislative and administrative power to take forward development programs. Industry: It has the strength of technology and managerial skills required to identify solutions and execute projects in a time-bound manner. NGOs and other Institutions: They penetrate deep into the community to propagate ideas and act as a vibrant feedback mechanism. We have always believed that enhancing the social well-being of individuals would add a lot more meaning to our overall business existence. Caring for the people and the

community has therefore been an important facet of our business philosophy. We are happy that we have influenced the lives of several people in the vicinity of our facilitates through the several initiatives and programmes undertaken by the Trust. All donations/contributions to The Orchid Trust are exempt from Income Tax under section 80G. For more information on our corporate responsibility efforts and to collaborate with us, kindly contact: The Project Co-ordinator Orchid Trust 2nd Floor, 'Crown Court' #128, Cathedral Road Chennai 600 086, India Ph: +91 - 44 - 2811 0914 Email:

Focus Areas Orchid Trust's key thrust areas

Education Health Self Employment Capacity Building Community Asset Development

The Trust has adopted 24 villages and 6 panchayats and work continuously in implementing several welfare schemes in key-identified thrust areas like education, health, self-employment, capacity building, community asset development and youth development etc. Education - Lighting the Life One tree can make a million matches and one match can destroy a million trees. Orchid Trust believes in building up society with a strong educational base embedded with noble humanistic values. Hence, it aims at facilitation and educational endeavours of the children making them generators like trees. Orchid Trust has thus initiated and continues to implement several activities that aim at improving the educational inputs in the neighbourhoods, especially those that target children from poor households.

Healthcare - Step towards creation of Healthy Family To promote health awareness and to provide medical facilities to the needy especially to those who are devoid of health facilities either due to financial crunch or due to being in far flung areas. Orchid Trust has consistently focused on health issues in the neighbourhood. Orchid fills the gap and proactively helps to meet the unmet health needs of the community. Youth Empowerment - Moulding the Future. Youth spearheads the direction of the society. Hence, adequate support and opportunities need to be provided to tap their potential appropriately. Problems such as unemployment, drug addiction, alcoholism, frustration, anger that plague the society today needs to be addressed in a timely manner. Orchid Trust has evolved strategies to prepare the unemployed rural youth to succeed in realising their dreams and contribute back to the society. Women Empowerment - Towards sustainable growth Orchid Trusts intervention in womens development stems from the understanding that women are the primary agents of family and community development. Women invest all their income in their families. Hence it is important that they have access to and control over income. Orchid Trust initiatives in this sector are geared towards this. Orchid Trust organises regular group meetings to understand the SHGs (Self Help Groups) as well as to motivate them to function optimally. We have adopted 140 women self help groups having more than 1800 SHG members in 25 villages to improve their economic condition through income generation programmes. Community Asset Creation - Enhancing the quality of Life We have embarked on a number of initiatives in supplementing the existing village infrastructure with additional assets. Significant money has been invested in the area of community asset creation by evoking public participation. Infrastructure like school buildings, community halls, tuition centres, primary health centres, streetlights, drinking water wells, water coolers etc. have been provided by the Trust.

Employee Involvement
Our strong belief in community involvement encourages our people to take part in local projects. This helps in developing valuable skills.

Product profile

Brand Name ESAMLO - AT 10'S ESAMLO 2.5 10'S Generic Name S (-) Amlodipine Besilate and Atenolol Tablets S (-) Amlodipine Besilate Tablets

ESAMLO 5 10'S INDAP 2.5 10'S INDAP AT 10'S INDAP SR 1.5 10'S LOSAVAS 25 10'S LOSAVAS 50 10'S LOSAVAS H 50 10'S METO AM 25 10S METO AM 50 10S METO ER 100 10'S METO ER 12.5 10S METO ER 25 10'S METO ER 50 10'S METO ER HT 25 10S METO ER HT 50 10S OLSAVAS 20 10S OLSAVAS 3 10S OLSAVAS 40 10S OLSAVAS AM 10S OLSAVAS H 20 10S OLSAVAS H 40 10S LOL SR 40 10S LOL SR 80 10'S MANOPROLOL 10 10'S MANOPROLOL 20 10'S MANOPROLOL 40 10'S AMLO - AT 10'S AMLO - L 10'S AMLO 10 10'S

S (-) Amlodipine Besilate Tablets Indapamide tablets USP Indapamide with Atenolol tablets Indapamide sustained release tablets Losartan potassium tablets Losartan potassium tablets Losartan potassium with hydrochlorothiazide tablets Metoprolol ER with Amlodipine Tablets Metoprolol ER with Amlodipine Tablets Metorolol Succinate Extended Release tablets USP Metorolol Succinate Extended Release tablets USP Metorolol Succinate Extended Release tablets USP Metorolol Succinate Extended Release tablets USP Metoprolol ER with Hydrochlorothiazide Tablets Metoprolol ER with Hydrochlorothiazide Tablets Olmesartan Medoxomil Tablets Olmesartan medoxomil, Hydrochlorothiazide and amlodipine tablets Olmesartan Medoxomil Tablets Olmesartan Medoxomil and Amlodipine tablets Olmesartan Medoxomil and Hydrochlorothiazide tablets Olmesartan Medoxomil and Hydrochlorothiazide tablets Propranolol HCl sustained release capsules USP Propranolol HCl sustained release capsules USP Propranolol Tablets IP Propranolol Tablets IP Propranolol Tablets IP Amlodipine Besilate and Atenolol Tablets Amlodipine Besilate and Lisinopril Tablets Amlodipine tablets IP


Amlodipine tablets IP Amlodipine tablets IP Torsemide Tablets Torsemide Tablets Torsemide Tablets Altenolol Tablets IP Altenolol Tablets IP Nebivolol Tablets IP Nebivolol Tablets IP Ramipril capsules Ramipril capsules Ramipril capsules Ramipril and Hydrochlorothiazide Tablets Telmisartan Tablets Telmisartan Tablets Telmisartan Tablets Telmisartan and Hydrochlorothiazide Tablets Telmisartan and Amlodipine Tablets Trimetazidine HCl tablets Trimetazidine HCl tablets Clopidogrel Tablets USP Clopidogrel and Asprin Tablets Clopidogrel and Asprin Tablets Tirofiban 5 mg Atorvastatin tablets Atorvastatin tablets Atorvastatin tablets Atorvastatin and Fenofibrate Tablets Atorvastatin and Fenofibrate Tablets


Atrovastatin and Ezetimibe tablets Fenofibrate tablets Rosuvastatin Tablets IP Rosuvastatin Tablets IP Rosuvastatin Tablets IP

Brand Name G.REG 10'S G.REG SR 1000 10'S G.REG SR 500 10'S GLIMTIDE 1 10'S GLIMTIDE 2 10'S GLIMTIDE 4 10'S GLIMTIDE FORTE 10'S GLIMTIDE PLUS 10'S PIOCON 15 10'S PIOCON 30 10'S PIOCON FORTE 10S PIOCON PLUS 10S VOBIS 0.2 10S VOBIS 0.3 10S VOBIS M 0.2 10S VOBIS M-0.3 ACARB 25 10'S ACARB 50 10'S BENFORMIN - LS 10'S BENFORMIN 10'S Generic Name Metformin HCL tablets IP Metformin HCl sustained release tablets Metformin HCl sustained release tablets Glimipride Tablets Glimipride Tablets Glimipride Tablets Glimepiride and Metformin ( extented release )Tablets Glimepiride and Metformin ( extented release )Tablets Pioglitazone Tablets Pioglitazone Tablets Pioglitazone with Metformin Tablets Pioglitazone with Metformin Tablets Voglibose tablets Voglibose tablets Voglibose and Metformin HCl (Sustained release)tablets Voglibose and Metformin HCl (Sustained release)tablets Acarbose tablets IP Acarbose tablets IP Metformin HCL and Glibenclamide Tablets Metformin HCL and Glibenclamide Tablets


Metformin HCL and Glibenclamide Tablets Metformin HCL and Gliclazide Tablets Metformin HCL and Gliclazide Tablets Gliclazide Tablets BP Gliclazide Tablets BP Repaglinide tablets USP Repaglinide tablets USP Glimepride, Pioglitazone and Metformin (ER) Tablets Glimepride, Pioglitazone and Metformin (ER) Tablets

Brand Name ALZEPIL 10 10S ALZEPIL 5 10S 2-DEP-20 2-DEP-30 AMICHLOR - DS 10'S AMICHLOR 10'S AMIT 10 10'S AMIT 25 10'S AMIT 50 10'S AMIT 75 10'S DOTH 100 10'S DOTH 25 10'S DOTH 50 10'S DOTH 75 10'S FLUTHIXOLE 10S Generic Name Donepezil Hydrochloride tablet IP Donepezil Hydrochloride tablet IP Duloxetin Tablets Duloxetin Tablets Amitriptyline and Chlordiazepoxide Tablets USP Amitriptyline and Chlordiazepoxide Tablets USP Amitriptyline Tablets IP Amitriptyline Tablets IP Amitriptyline Tablets IP Amitriptyline Tablets IP Dothiepin HCl Tablets BP Dothiepin HCl Tablets BP Dothiepin HCl Tablets BP Dothiepin HCl Tablets BP Flupentixol and Melitracen Tablets

LINDEP 100 10'S LINDEP 50 10'S NOC 10 10'S NOC 20 10'S SALIDEP 40 10'S TOPDEP 10 10'S TOPDEP S 10 10'S TOPDEP S 20 10'S BIOCOBAL P75 10S BIOGABA 10S PNA 100 10'S PNA 200 10'S RISCALM - LS 10'S TOPSULANT 100 10S TOPSULANT 25 10S TOPSULANT 50 10S VALP ER 250 10'S VALP ER 500 10S ZAC 10 10'S ZAC 5 10'S FLUGRAINE 10 10'S FLUGRAINE 5 10'S DINE 2.5 10'S DINE 5 10'S MANOHEXY 10'S MANOHEXY 5 10'S AMISELECT 100 10S AMISELECT 200 10S AMISELECT 50 10S

Sertraline tablets Sertraline tablets Fluoxetine capsules USP Fluoxetine capsules USP Fluoxetine capsules USP Citalopram hydrobromide tablets Escitalopram tablets Escitalopram tablets Pregabalin and Mecobalamin capsules Gabapentin Mecobalamin and Alpha Lipoic Acid Tablets Phenytoin sodium tablets IP E Phenytoin sodium tablets IP Risperidone and Trihexyphenidyl HCl Tablets Topiramate Tablets Topiramate Tablets Topiramate Tablets Divalproex sodium ER Tablets Divalproex sodium ER Tablets Clobazam tablets Clobazam tablets Flunarizine Tablets Flunarizine Tablets Procyclidine HCl tablets IP Procyclidine HCl tablets IP Trihexyphenydil HCl Tablets Trihexyphenydil HCl Tablets Amisulpride Tablets Amisulpride Tablets Amisulpride Tablets


Clozapine tablets USP Clozapine tablets USP Trifluoperazine HCl,Trihexyphenidyl and Chloropromazine HCl Tablets Trihexyphenydil HCl and Trifluoperazine Tablets Haloperidol and Trihexyphenidyl Tablets Haloperidol and Trihexyphenidyl Tablets Olanzapine tablets Olanzapine tablets Olanzapine tablets Olanzapine tablets Risperidone tablets Risperidone tablets Risperidone tablets Risperidone tablets

RISCALM FORTE 10'S Risperidone and Trihexyphenidyl HCl Tablets RISCALM PLUS 10'S GOVERT 16 10S GOVERT 24 10S GOVERT 8 10S L.PAM 1 10'S L.PAM 2 10'S L.PAM 3 10'S LORA INJ 2ML MANOREST 0.25 10'S MANOREST 0.5 10'S MANOREST 1 10'S ZEE 0.5 10'S Risperidone and Trihexyphenidyl HCl Tablets Betahistine dihydrochloride dispersible tablets Betahistine dihydrochloride dispersible tablets Betahistine dihydrochloride dispersible tablets Lorazepam Tablets BP Lorazepam Tablets BP Lorazepam Tablets BP Lorazepam Tablets BP Alprazolam Tablets IP Alprazolam Tablets IP Alprazolam Tablets IP Clonazepam Tablets USP


Clonazepam Tablets USP Clonazepam Tablets USP Citicoline Tablets Citicoline Injection Idebenone tablets Piracetam capsules Piracetam Injection

DISULFIRAM 250 10'S Disulfiram Tablets IP RESENZ 75 10S Pregabalin capsules

Nutritional Supplements
Brand Name CALPIDA 10S DIACOBAL - S 10'S DIACOBAL 1.5MG 10'S DIACOBAL PLUS 1 10S DIACOBAL PLUS 1 INJ DIACOBAL SYRUP 1 200ML DIACOBAL VIT 1 INJ OXIBET (DIETARY) 10S VITAMIN C INJ BENFAGE FORTE 10S BENFAGE PLUS 10S BENFO PLUS 10S BIOCOBAL 1.5MG 10'S BIOCOBAL 500 MCG 10'S Calcium Orolate tablets Mecobalamin Tablets Mecobalamin Tablets Pyridoxine HCl, Mecobalamin and Nicotinamide tablets Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml PyridoxineHCl,Mecobalamin and Lysine HCl syrup Vitamin C IP, Mecobalamin, folic acid and Niacinamide injection Anti-Oxidants, Vitamins and Minerals Capsules Vitamin C injection IP Pyridoxine HCl, Mecobalamin, Benfothiamine, Inositol and Alpha lipoic acid capsules Pyridoxine HCl ,Mecobalamin,Benfothiamine, and folic acid tablets Pyridoxine HCl, Mecobalamin,Benfothiamine, and folic acid tablets Mecobalamin Tablets Mecobalamin Tablets Generic Name


Methylcobalamin injection Mecobalamin and Vitamin tablets Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml Pyridoxine HCl, Mecobalamin and Nicotinamide tablets Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml PyridoxineHCl,Mecobalamin and Lysine HCl syrup Mecobalamin Tablets Ginkobiloba 60mg, Ginseng 42.5mg, Garlic 2mg Softgels Pyridoxine HCl, Mecobalamin, Benfothiamine, Inositol and Alpha lipoic acid capsules Mecobalamin tablets Methylcobalamin injection Mecobalamin and Vitamin tablets Methylcobalamin, Pyridoxine HCl and Niacinamide injection Pack 2 ml Lycopene, Selenium and Vitamin E Capsules Acetylcysteine, Vit. C, E and A with Selenium, Chromium Capsules Enoxaparin 40 mg Enoxaparin 60 mg

Brand Name XENOCET 10S CEFACURE 100 DROPS CEFACURE 250MG 10S DT Generic Name Levocetirizine Tablets IP Cephalexin Cephalexin Dispersible Tablets

OCPL CEFACURE 500MG CAPS 10S - OCPL CEPOTIL 100MG 4S TABS OCPL CEPOTIL 200MG 4S TABS OCPL SPIZEF 250MG TABS 4S OCPL SPIZEF 500MG TABS 4S OCPL ORNIWELL 10S VOCOZO 200mg VOCOZO 200mg Inj PODOBID 200MG TABS 10S PODOBID 50 DRY SYRUP PODOBID DT 100MG TABS 10S PODOBID DT 50MG TABS 10S ZAFIL 50 DRY SYRUP ZAFIL DT-100 10S ZAFIL-200 10S EVERCEF 250 4'S EVERCEF 500 4'S MACROAZI 250 6S MACROAZI 500 3S ORFIX 200 10S TAB ORFIX CV 10S ORFIX DT 100MG 10S OCPL ORFIX-DT 50MG TAB 10S Cephalexin Dispersible Tablets Cefpodoxime Proxetil Tablets USP Cefpodoxime Proxetil Tablets USP Cefuroxime Axetil Tablets USP Cefuroxime Axetil Tablets USP Ofloxacin & Ornidazole Tablets Voriconazole Voriconazole Cefpodoxime Proxetil Tablets USP Cefpodoxime Proxetil Oral Suspension IP Cefpodoxime Proxetil Tablets USP Cefpodoxime Proxetil Tablets USP Cefixime Oral Suspension IP Cefixime Dispersible Tablets Cefixime Tablets IP Cefuroxime Axetil Tablets USP Cefuroxime Axetil Tablets USP Azithromycin Tablets IP Azithromycin Tablets IP Cefixime Dispersible Tablets Cefixime and Clavulanate Potassium Tablets Cefixime Dispersible Tablets Cefixime Dispersible Tablets


Cefixime and Ofloxacin Dispersible Tablets Cefixime and Ofloxacin Tablets Cefoperazone 500 mg + Sulbactum 500 mg Cefoperazone1g + Sulbactum1g Cefoperazone 1g + Sulbactam 0.5g Cefoperazone 2g + Sulbactam 1g Ceftriaxone 1 g Ceftriaxone 250 mg Ceftriaxone 500 mg Ceftriaxone 1000 mg + Tazobactam 125 mg Cefpirome 1g Tigecycline Cefepime 1g + Tazobactam 125 mg Doripenem Meropenem 0.5 g Meropenem 1g Meropenem 250 mg Tramadol 1 ml Tramadol 2 ml Tramadol 50 mg Amikacin 100 mg Amikacin 250 mg Amikacin 500 mg Linezolid 600 mg Cefepime Hydrochloride 1g Ceftazidime 1g Ceftazidime 250 mg Ceftazidime 2g Cefuroxime Axetil 250 mg


Cefuroxime Axetil 500 mg Cefuroxime Sodium 1.5 g Cefuroxime Sodium 750 mg Teicoplanin 400 mg Cefotaxime Sodium 1 g Cefotaxime Sodium 250 mg Cefotaxime Sodium 500 mg Cefotaxime 1 g + Sulbactum 500 mg Feropenem Sodium 200 mg Imipenem 500mg + Cilastatin 500 mg Piperacillin 2g & Tazobactam 0.25 gm Piperacillin 4g & Tazobactam 0.5 gm

THERMGO 120 SUSPENSION Paracetamol Suspension USP THERMGO 250 SUSPENSION Paracetamol Suspension USP THERMGO DROPS THERMGO DT 250 10S THERMGO-650 10S THERMGO DT 250 10S ELPIZOLE-20 10S ELPIZOLE-D 10S MANEZ 20 10S MANEZ 40 10S MOBIUM 10'S XENORAB-DSR 10S XENOCOF A 100ML XENOCOF D 100ML XENOCOF 100ML Acetaminophen Oral Suspension USP Paracetamol Tablets IP Paracetamol Tablets IP Paracetamol Tablets IP Rabeprazole tablets IP Rabeprazole (EC) and Domperidone (SR) capsules Pantoprazole tablets Pantoprazole tablets Calcium dobesilate monohydrate capsules Rabeprazole and Domperidone SR Capsules Terbutaline Sulphate, Bromhexine HCl, Guaiphenesin with Menthol Chlorpheniramine maleate, codeine phosphate and menthol syrup Ambroxol, Guaiphenesin, Phenylephrine, Chlorpheniramine maleate with menthol


Lactulose solution USP Kit tablets of Mifepristone and Misoprostol Etodolac tablet USP Etodolac extended release tablet USP Etodolac extended release tablet USP Lornoxicam Tablets Aceclofenac and Paracetamol tablets Aceclofenac,paracetamol,and serratiopeptidase tablets Aceclofenac and Thiocolchicoside tablets

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute as an offer for sales in territories where it is not permitted by law.

API (Active Pharmaceutical Products) Cephalosporins - Orals

Product Cefalexin Cefadroxil Cefixime Cefradine Cefuroxime Axetil (Amorphous) Cefuroxime Axetil (Crystalline) Cefprozil Cefditoren Pivoxil (Amorphous) Pharmacopeia EP / BP / USP / JP EP / BP / USP / JP EP / BP / USP USP / EP / BP USP / EP / BP / JP USP USP In-house DMF Availability COS -

Cefditoren Pivoxil (Crystalline) Cefdinir Cefpodoxime Proxetil Ceftibuten Cefcapene Pivoxil Hydrochloride Ceftamet Pivoxil

USP / JP USP / JP USP / EP / JP In-house JP JP


Cephalosporins - Injectibles
Product Cefotaxime Sodium (Sterile) Ceftriaxone Sodium (Sterile) Ceftazidime Pentahydrate with Sodium Carbonate for Injection Cefazolin Sodium (Sterile) Cefoxitin Sodium (Sterile) Cefepime + Arginine (Sterile) Cefpirome Sulphate Cefuroxime Sodium (Sterile) Ceforanide + L-Lysine Cefalothin Sodium Buffered (Sterile) Ceftizoxime Sodium (Sterile) Cefoperazone Sodium (Sterile) Cefotiam Hexetil Cefotiam Hydrochloride Cefozopran Hydrochloride Pharmacopeia USP / EP/BP/JP USP / EP USP / EP/BP/JP USP / EP/BP/JP USP / EP/BP USP In-house USP / EP USP EP USP JP / EP JP JP JP DMF availability TIP TIP TIP TIP COS -

Veterinary Products
Product Cefalonium Cefquinome Sulphate (Sterile) Ceftiofur Hydrochloride Ceftiofur Sodium (Sterile) Pharmacopeia BP In-house USP In-house DMF availability COS -

Product Meropenem Imipenem + Cilastatin Doripenem Biapenem Pharmacopeia USP / JP USP / EP/BP/JP In-house In-house DMF availability TIP COS -

Product Aripiprazole Armodafinil Dexlansoprazole Duloxetine Hydrochloride Eszopiclone Felodipine Granisetron Hydrochloride Ibandronate Sodium Levetiracetam Pharmacopeia In-house In-house In-house In-house In-house USP / EP/BP EP/BP In-house USP/EP DMF availability COS -

Memantine Hydrochloride Modafinil Naratriptan Hydrochloride Nisoldipine Paliperidone Phenytoin Sodium Pramipexole Dihydrochloride Quetiapine Fumarate Rabeprazole Sodium Rasagiline Mesylate Rivastigmine Tartrate Ropinirole Hydrochloride Sumatriptan Succinate Tadalafil Telmisartan Terbinafine Hydrochloride Tolterodine Tartrate Zaleplon Zolmitriptan

In-house USP / EP USP In-house JP USP/EP/BP EP USP/EP In-house In-house In-house In-house USP /EP/BP In-house USP / EP USP / EP/BP In-house USP In-house

Product Ampicillin+Sulbactum Piperacilin+Tazobactum


Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute as an offer for sales in territories where it is not permitted by law.

Active Pharmaceutical Ingredients Alathur, Chennai Antibiotic (Cephalosporin) API

Our API manufacturing plant located at Alathur, south of Chennai is one of the largest integrated antibiotic manufacturing complexes in India and specialises in the manufacture of cephalosporin active pharmaceutical ingredients (APIs). Set in a large industrial estate, the complex is a massive, state-of-the-art, most modern manufacturing complex that produces a wide range of cephalosporin bulk activities spread across different generations of cephalosporin bulk actives. Its world-class crystallisation and lyophillisation facilities have not only provided a global competitive edge, but have also helped achieve manufacturing excellence and differentiation. With a capability to handle highly complex and hazardous reactions with utmost safety and efficiency, the plants operations are backed by a full spectrum of utilities including a captive power generation plant, high technology solvent recovery facilities, sophisticated quality control equipment and a 'zero-discharge' environment friendly effluent treatment plant. Our manufacturing complex has been successfully audited and approved time and again by leading global regulatory agencies like the US FDA, UK MHRA, GMP, EDQM, TGA (Australian), Danish Medicines Agency, in addition to several quality, environment and safety management recognition.


Aurangabad, Maharastra - Antibiotic (Penicillin and Carbapenems) and Nonantibiotic API

Our API manufacturing complex in Aurangabad, near Mumbai provides multi-therapeutic product offerings comprising high-end betalactams, carbapenems and non-penicillin, noncephalosporin (NPNC) APIs. Spread across a large expanse, this facility is a world-class API manufacturing complex which can handle complex synthesis and reactions with the highest levels of safety and productivity. This infrastructure uses complex gases and a high technology hydrogenator system. World-class

utilities, solvent recovery systems and quality control infrastructure support the operations. This manufacturing complex has also received global accolades for its environment, operational efficiency and safety management systems. The facility has also been approved by leading regulatory agencies.

Formulations Irungattukottai, Chennai - Oral Formulations (Generics)

Our modern oral formulations manufacturing facility at Irungattukottai (IKKT), near Chennai has modern infrastructure geared to offer high throughput. Coupled with world-class R&D labs, this formulations infrastructure is in the forefront of our successful entry into the advanced markets of US and Europe. With a vast site area, our oral formulations facility manufactures various types of dosage forms such as oral tablets and capsules in diverse dosage strengths and product categories. The facility has been inspected and approved by leading regulatory agencies including the US FDA, UK MHRA, MCC (South Africa) and Danish Medicines Agency, based on specific filings. Several ANDAs (abbreviated new drug applications) have been filed from this complex with approvals and new launches underway. The formulations facility also houses a modern R&D centre for pharmaceuticals research.

Alathur, Chennai - Oral Formulations (Emerging)

Oral non-cephalosporin formulations facility Our oral non-cephalosporin formulations facility specialises in the manufacturing of nutraceutical products. The facility produces a range of dietary supplements for the advanced markets. Many other high-value products like anti-diabetics, cardio vascular drugs (CVS), antidepressants and anti-epileptics are manufactured in this facility to cater to the emerging markets. Built to GMP (good manufacturing practices) standards (WHO guidelines), this facility has stateof-the-art packaging machinery and a full-spectrum, dedicated quality control and microbiological services, adding distinctiveness to the manufacturing quality. Designed for optimal operating conditions and uni-directional flow of resources and materials, the facility has been approved by the Australian-TGA and is being offered for inspection by several other

leading international regulatory agencies. Oral cephalosporin formulations facility Our oral cephalosporin formulations facility manufactures cephalosporin oral products dedicated to the domestic and emerging markets. The facility has the capability to manufacture different dosage forms like tablets, capsules, dry syrups and liquid orals. The facility conforms to cGMP standards and is approved by the WHO.

Apart from providing quality and affordable generic drugs to the global healthcare system, focus on R&D is a key value driver at Orchid. We recognise the importance of developing knowledgeintensive businesses as drivers of future growth. Orchid is a partner of choice to select global pharma companies in the areas of new chemical entity (NCE) development, novel drug delivery systems (NDDS) development, custom synthesis and R&D services. Our R&D Centres located in Chennai are GLP (Good Laboratory Practice) certified and equipped with sophisticated analytical and chemical laboratory equipment, supported by a good technical infrastructure for discovering and developing new drugs. Our scientific personnel comprise of over 600 scientists across the entire spectrum of R&D and analytical research, working in various areas of drug discovery and development in addition to CMC (chemistry, manufacturing and controls), pharma research and other related processes and pharma research activities. Our people strive to create clinically differentiated drugs and diagnostics to help people live longer and healthier. To drive a stronger focus in the discovery and development area, we have developed a proprietary product pipeline and collaborated with multinational companies for discovery of new chemical entities to undertake co-discovery and/or co-development projects, as well as provide custom research services.

R&D Infrastructure
Our core competence has always been in state-of-the-art development and manufacturing infrastructure. We have four R&D divisions dedicated to process research, drug discovery and development, pharmaceutical research and biotechnology. These research facilities are in the vanguard of creating generic product pipelines, proprietary discovery pipelines, novel processes and formulations, each aimed at building valuable intellectual property. From modeling of a new drug candidate in silico to its validation in an animal model, we are capable of conducting all research activities in-house. Sophisticated equipment and modern bioinformatics provide an edge to Orchid's drug discovery activities. The National Good Laboratory Practices (GLP) Monitoring Authority of India, aligned to OECD Principles of GLP has also certified our R&D facilities for GLP compliance.

Our end-to-end connected infrastructure, which enables complete value-chain integration, remains a key driver of our growth in the diverse and differentiated arenas of generic and discovery research, encompassing the entire pharmaceutical spectrum.

We are fully capable of meeting challenges of modern-day drug discovery, given our infrastructure and the competencies for innovative medicinal chemistry and biology as well as the deployment of sharper efficacy and safety screens. We have one of the most comprehensive research programs in the Indian pharmaceutical field. Spread across two campuses of 12 acres in Chennai, the research initiatives are divisionalised into core areas. Together, these streams signify the generation of vital intellectual property.

Research Process Research

Our process research team is focused on developing patentable non-infringing processes for the company's operations in the regulated markets.

Pharma Research
The pharma research division covers both the antibiotic and non-antibiotic segments with specific departments for the domestic markets, other emerging markets and regulated markets. A specialised veterinary formulations program is also underway.

New Drug Discovery

Orchid's strong NDD pipeline encompasses high-growth therapeutic segments like anti-diabetic, oncology among others. Orchids multi-therapeutic, multi-lead portfolio and selective partnerships with global customers for R&D projects reflects its emergence in the global drug discovery space as a potential player. Orchids R&D stands out in the drug discovery domain with the right mix of infrastructure, knowledge and business orientation, with faster decision making and execution excellence, re-enforcing its position as a preferred partner. The infrastructure comprises of independent laboratories for medicinal chemistry, analytical chemistry, molecular modeling, pharmacology & pharmacokinetics and molecular biology. Lead molecules have been identified in two therapeutic areas anti-infectives and pain management based on confirmatory microbiological and pharmacological studies. Pre-formulation and other studies are also in progress for further lead optimisation. Furthermore, our medicinal chemistry

division has well trained scientists who perform design and synthesis of novel molecules in various therapeutic areas such as anti-infectives, anti-inflammatory, anti-cancer and metabolic disorders. They interact with the drug design group to synthesise second-generation patentable molecules that are either inspired by natural products or successfully marketed in these therapeutic areas.

Pre-Clinical Research
Our pre-clinical facility (PCF) undertakes a wide range of studies, including regulatory toxicity which are required for filing Investigational New Drug (IND) applications. A number of new screening facilities and biological evaluation models have been set up to support the drug discovery and development process. A wide range of animal toxicology, microbiology and pharmacology studies are also undertaken to confirm the safety and efficacy of molecules. The facility is registered with the committee for the Purpose of Control and Supervision of Experiment on Animals (CPCSEA), Ministry of Environment & Forests and the Government of India. Additionally, an Institutional Animal Ethics Committee (IAEC) monitors our research for issues related to animal welfare and experimentation. Work quality standards are in compliance with US Food Drug Administration (US FDA) and the Organisation for Economic Co-operation Development (OECD) principles of Good Laboratory Practice (GLP).

New Drug Delivery Systems

Pioneering research to devise newer strategies for effectively delivering the drugs in the body or improvise the existing technologies to enhance their efficiency is the need of the hour. The ever improving delivery systems are not only beneficial to the patients as they are less cumbersome and easy to abide by but also reduce the complications associated with the induction of the drug in the body. At Orchid, we focus on developing novel drug delivery systems (NDDS) for select anti-infective molecules. A few platform and product specific technologies with six prototype formulations have been successfully developed.

Areas of NDDS Research

Drug specific Platform technologies Disease conditions

Biotech Research
Our biotech research is focused on replacing existing chemical methods of manufacturing various intermediates, with fermentation and enzymatic based transformations to improve

environmental safety. Capabilities include:

PCR and Directed evolution of proteins Gene cloning Protein expression and purification High-throughput screening Development of assays for proteins in the cephalosporin pathway

Intellectual Property Management

We have been a leading generator of intellectual property in the Indian pharmaceutical industry. The IPM department supports development of patent applications, files patents, supports the development of patent applications and identifies potential new products and markets for APIs and formulations besides supporting research activities. Orchid's Intellectual Property Management (IPM) department comprise of qualified and experienced personnel to support its operations. Several filings have been made in the areas of new drug discovery (NDD) and novel drug delivery systems (NDDS) across various national and international patent offices. Several patents have been published and granted in the areas of drug discovery and other cutting-edge spaces. In the near future, further acceleration in the filing process with the publication and grant of patents is expected.

CRAMS (Contract Research and Manufacturing Services)

We have distinctively and rapidly evolved into a fully integrated Indian pharmaceutical Company, straddling the pharmaceutical chain with its presence in all six clusters of APIs, CRAMS, branded generics, regulated generics, NDDS (Novel Drug Delivery Systems) and NCEs (New Chemical Entities). Leveraging our world-class R&D base, we have taken up Contract Research and Manufacturing Services (CRAMS) as a discrete initiative and advanced, especially in the areas related to new drug products, NDDS and NCEs. Over the years, Orchid Research's continuous investment in research and manufacture has positioned it as a global CRAMS partner. This initiative connects Orchid Research's discovery capabilities with the group's industrial-scale manufacturing capabilities. As a result, Orchid Research centrally positions itself in the drug discovery domain with the right mix of infrastructure, knowledge and business orientation. With CRAMS, we also reinforce our

position as a preferred global partner with the potential to undertake a wide range of projects on a 'FTE' or 'fee for service' basis.

Our service value proposition includes

Offering dedicated teams and manufacturing lines for full-scale commercial manufacture

Leveraging resident drug discovery experience in multi-therapeutic and multi-lead discovery programmes

Providing business flexibility with early phase to proof-of-concept collaboration, enabling contract research and development projects across multiple domains

Scaling chemical development to a technologically efficient and cost-effective manner through the intelligent use of process optimisation and CMC (chemistry, manufacturing and controls) skills

Investing ethical values in our business activities, reflected in important knowledge protection initiatives and building walls to teams working for partner companies and protecting intellectual property

Manufacturing lab-scale, pre-clinical and clinical scale supplies

In this domain, we have master service agreements with Pfizer, covering both animal health and human health applications, under the aegis of which several projects have been either executed or currently in the pipeline. We are in discussions with other innovator firms for contract research and manufacturing agreements.

Spirit of Orchid!
At Orchid, human resources are our most valuable asset. We take an entrepreneurial approach that urges high performance standards from our employees through collaborative management. Over the years, our research products and initiatives have touched generations of people in India and abroad. We started commercial operations in 1994 and today we have reached a stage, which

facilitates enhanced value creation. The company as a whole represents a synergy of active talent at work, in generating remarkable performance with a single-minded commitment to produce extraordinary results and achieve the highest standards of quality in all spheres. Experts say 'quite an achievement', but we differ. We call it the 'Orchidian spirit' - the spirit that inspires 4000 plus people to challenge conventions, break with the past, work better, try harder and grow bigger. At Orchid, no matter what the odds, we believe in the dictum: tough times dont last, tough people do. In short, make a difference each day to the life we lead, the organisation we work for, the nation we are proud of and the planet we live in.

Our Secret Ingredients

Our remarkable growth across multiple therapies and geographies is primarily driven by an empowered culture to experiment, innovate and perform. Our core values of respect for human resource and empowerment have emerged as a unique cohesive force, complementing established and new skill-sets with an integrated, motivated organisation. We try to create an organisation wherein you put all the warmth, affection and care and what you get in return is excellence in all forms.

Work Environment
Here at Orchid, we offer an environment where growth is based on the ability to contribute, perform and achieve focus is to bring out your best strengths. We are proud to celebrate our people people trying harder, people taking risks, people making breakthrough innovations, people breaking barriers to collaborate, people determined to prove a point. Walk around our workspaces and you will feel the positive energy. Minds are constantly in motion researching, innovating and creating ideas. It is this mindset, which sets us apart.

Diversity and inclusion

Diversity is one of our special ingredients for success. We believe diversity is essential for building an enriching work environment. We include everyone and exclude no one. People from all parts of the world with different backgrounds are welcomed at the workplace. We encourage people to set their own goals in order to achieve excellence. Within our common purpose, we encourage people to embrace their individuality and grow.

Work-Life balance

Success is achieved when one finds the right balance between the demands on the professional front and the accomplishment of personal goals. We, at Orchid try to create that flexible environment for our people in the way we work and the things we do.

Why become an Orchidian?

We provide our employees a dynamic, professional environment bound by one spirit The 'Orchidian Spirit' which makes Orchid a great place to work. Our defined set of values and culture reflects our shared accountability for business goals, our aggressiveness in pursuing these goals, ways to achieve these goals and our adaptability in finding new and better products. We offer a host of career opportunities in all aspects of pharmaceutical research, manufacturing and marketing as well as corporate support functions. It is the people here who bring about the positive difference in the quest towards achieving higher levels of growth and profitability in the years to come.

We constantly encourage our employees to raise the bar, extend the limit. Our people handle multiple responsibilities and stretch the limits of what is possible and what is not. We keep our people intellectually stimulated and give them the freedom to make their own decisions, instilling in them a responsibility to help in the advancement of both the self and the company. At Orchid, there are several programmes offered to employees with opportunities to acquire and develop functional, people management and decision-making skills, enabling success at work.

Grow with Us
To us, our people are the key drivers of our success. Our commitment to training and development is a core value. That is why we invest greatly in training and development, both on and off the job, for the continuous enhancement of knowledge, skills and capabilities of our employees. As we grow, so do our people, developing new capabilities to take our business ahead. We would be pleased to have your resume on file for any available positions and will review it should an opening arise.